OncoMatch/Clinical Trials/NCT06475417
Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric Cancer
Is NCT06475417 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Adebrelimab combined with DOS for gastric cancer.
Treatment: Adebrelimab combined with DOS — To evaluate the efficacy and safety of adebrelimab combined DOS in neoadjuvant treatment of locally advanced resectable gastric cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Gastric Cancer
Disease stage
Required: Stage T2-3N+M0, T4ANANYM0
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
hemoglobin (hb) ≥ 90 g/l, absolute neutrophil count (anc) ≥ 1.5 × 10^9/l, platelets (plt) ≥ 80 × 10^9/l (no recent blood transfusions within 14 days)
Kidney function
serum creatinine (cr) ≤ 1.5 × uln or creatinine clearance rate (ccr) ≥ 60 ml/min
Liver function
total bilirubin (tbil) ≤ 1.5 × upper limit of normal (uln), alanine aminotransferase (alt) and aspartate aminotransferase (ast) ≤ 2.5 × uln
Cardiac function
left ventricular ejection fraction (lvef) ≥ lower limit of normal (50%)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06475417 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage T2-3N+M0 or T4ANANYM0 is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages